Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Association of rheumatoid arthritis risk alleles with response to anti-TNF biologics: results from the CORRONA registry and meta-analysis.

Pappas DA, Oh C, Plenge RM, Kremer JM, Greenberg JD.

Inflammation. 2013 Apr;36(2):279-84. doi: 10.1007/s10753-012-9544-4.

PMID:
23007924
2.

Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy.

Cui J, Saevarsdottir S, Thomson B, Padyukov L, van der Helm-van Mil AH, Nititham J, Hughes LB, de Vries N, Raychaudhuri S, Alfredsson L, Askling J, Wedrén S, Ding B, Guiducci C, Wolbink GJ, Crusius JB, van der Horst-Bruinsma IE, Herenius M, Weinblatt ME, Shadick NA, Worthington J, Batliwalla F, Kern M, Morgan AW, Wilson AG, Isaacs JD, Hyrich K, Seldin MF, Moreland LW, Behrens TW, Allaart CF, Criswell LA, Huizinga TW, Tak PP, Bridges SL Jr, Toes RE, Barton A, Klareskog L, Gregersen PK, Karlson EW, Plenge RM.

Arthritis Rheum. 2010 Jul;62(7):1849-61. doi: 10.1002/art.27457.

3.

Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment.

Tan RJ, Gibbons LJ, Potter C, Hyrich KL, Morgan AW, Wilson AG, Isaacs JD; BRAGGSS, Barton A.

Ann Rheum Dis. 2010 Jun;69(6):1029-35. doi: 10.1136/ard.2009.118406. Epub 2010 May 5. Erratum in: Ann Rheum Dis. 2011 Aug;70(8):1519.

4.

Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways.

Potter C, Cordell HJ, Barton A, Daly AK, Hyrich KL, Mann DA, Morgan AW, Wilson AG; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS), Isaacs JD.

Ann Rheum Dis. 2010 Jul;69(7):1315-20. doi: 10.1136/ard.2009.117309. Epub 2010 May 6.

PMID:
20448286
5.

Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment.

Mathews RJ, Robinson JI, Battellino M, Wong C, Taylor JC; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS), Eyre S, Churchman SM, Wilson AG, Isaacs JD, Hyrich K, Barton A, Plant D, Savic S, Cook GP, Sarzi-Puttini P, Emery P, Barrett JH, Morgan AW, McDermott MF.

Ann Rheum Dis. 2014 Jun;73(6):1202-10. doi: 10.1136/annrheumdis-2013-203276. Epub 2013 May 17.

PMID:
23687262
6.

Replication of association of the PTPRC gene with response to anti-tumor necrosis factor therapy in a large UK cohort.

Plant D, Prajapati R, Hyrich KL, Morgan AW, Wilson AG, Isaacs JD; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate, Barton A.

Arthritis Rheum. 2012 Mar;64(3):665-70. doi: 10.1002/art.33381.

7.

The role of eight polymorphisms in three candidate genes in determining the susceptibility, phenotype, and response to anti-TNF therapy in patients with rheumatoid arthritis.

Ceccarelli F, D'Alfonso S, Perricone C, Carlomagno Y, Alessandri C, Croia C, Barizzone N, Montecucco C, Galeazzi M, Sebastiani GD, Minisola G, Fiocco U, Valesini G.

Clin Exp Rheumatol. 2012 Nov-Dec;30(6):939-42. Epub 2012 Dec 17.

PMID:
22992305
8.

The role of the FcGRIIIa polymorphism in modifying the association between treatment and outcome in patients with rheumatoid arthritis treated with rituximab versus TNF-α antagonist therapies.

Sarsour K, Greenberg J, Johnston JA, Nelson DR, O'Brien LA, Oddoux C, Ostrer H, Pearlman A, Reed G.

Clin Exp Rheumatol. 2013 Mar-Apr;31(2):189-94. Epub 2012 Dec 13.

PMID:
23294992
9.

Association of anti-CCP positivity and carriage of TNFRII susceptibility variant with anti-TNF-α response in rheumatoid arthritis.

Vasilopoulos Y, Bagiatis V, Stamatopoulou D, Zisopoulos D, Alexiou I, Sarafidou T, Settas L, Sakkas L, Mamouris Z.

Clin Exp Rheumatol. 2011 Jul-Aug;29(4):701-4. Epub 2011 Sep 1.

PMID:
21813066
10.

Genetic variants in toll-like receptors are not associated with rheumatoid arthritis susceptibility or anti-tumour necrosis factor treatment outcome.

Coenen MJ, Enevold C, Barrera P, Schijvenaars MM, Toonen EJ, Scheffer H, Padyukov L, Kastbom A, Klareskog L, Barton A, Kievit W, Rood MJ, Jansen TL, Swinkels D, van Riel PL, Franke B, Bendtzen K, Radstake TR.

PLoS One. 2010 Dec 15;5(12):e14326. doi: 10.1371/journal.pone.0014326.

11.

Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: a prospective case-only study.

Suarez-Gestal M, Perez-Pampin E, Calaza M, Gomez-Reino JJ, Gonzalez A.

Arthritis Res Ther. 2010;12(2):R72. doi: 10.1186/ar2990. Epub 2010 Apr 27.

12.

Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.

Hyrich KL, Watson KD, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register.

Rheumatology (Oxford). 2006 Dec;45(12):1558-65. Epub 2006 May 16.

13.

Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis.

Liu C, Batliwalla F, Li W, Lee A, Roubenoff R, Beckman E, Khalili H, Damle A, Kern M, Furie R, Dupuis J, Plenge RM, Coenen MJ, Behrens TW, Carulli JP, Gregersen PK.

Mol Med. 2008 Sep-Oct;14(9-10):575-81. doi: 10.2119/2008-00056.Liu.

14.

Tumour necrosis factor alpha -308G->A polymorphism is not associated with response to TNFalpha blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis.

Pavy S, Toonen EJ, Miceli-Richard C, Barrera P, van Riel PL, Criswell LA, Mariette X, Coenen MJ.

Ann Rheum Dis. 2010 Jun;69(6):1022-8. doi: 10.1136/ard.2009.117622. Epub 2009 Dec 4. Review.

PMID:
19966089
15.

B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.

Finckh A, Ciurea A, Brulhart L, Kyburz D, Möller B, Dehler S, Revaz S, Dudler J, Gabay C; Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis.

Arthritis Rheum. 2007 May;56(5):1417-23.

16.

Utilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arthritis in a United States observational cohort study.

Lee SJ, Chang H, Yazici Y, Greenberg JD, Kremer JM, Kavanaugh A.

J Rheumatol. 2009 Aug;36(8):1611-7. doi: 10.3899/jrheum.080889. Epub 2009 Apr 15.

PMID:
19369454
17.

Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study.

Iannaccone CK, Lee YC, Cui J, Frits ML, Glass RJ, Plenge RM, Solomon DH, Weinblatt ME, Shadick NA.

Rheumatology (Oxford). 2011 Jan;50(1):40-6. doi: 10.1093/rheumatology/keq263. Epub 2010 Sep 16.

18.

Genotype at the sIL-6R A358C polymorphism does not influence response to anti-TNF therapy in patients with rheumatoid arthritis.

Hassan B, Maxwell JR, Hyrich KL; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate, Barton A, Worthington J, Isaacs JD, Morgan AW, Wilson AG.

Rheumatology (Oxford). 2010 Jan;49(1):43-7. doi: 10.1093/rheumatology/kep372. Epub 2009 Nov 19.

19.

Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis.

Morales-Lara MJ, Cañete JD, Torres-Moreno D, Hernández MV, Pedrero F, Celis R, García-Simón MS, Conesa-Zamora P.

Joint Bone Spine. 2012 Dec;79(6):591-6. doi: 10.1016/j.jbspin.2012.02.003. Epub 2012 Apr 4.

PMID:
22480748
20.

Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.

Cañete JD, Suárez B, Hernández MV, Sanmartí R, Rego I, Celis R, Moll C, Pinto JA, Blanco FJ, Lozano F.

Ann Rheum Dis. 2009 Oct;68(10):1547-52. doi: 10.1136/ard.2008.096982. Epub 2008 Oct 17.

PMID:
18930989
Items per page

Supplemental Content

Write to the Help Desk